Key result
Low-dose aspirin demonstrated mixed efficacy in preventing preeclampsia across diverse high-risk populations, with significant reductions in specific subgroups like non-Hispanic white women (P = 0.007) but no universal benefit.
Why the study?
The study was conducted to evaluate the efficacy of low-dose aspirin in preventing preeclampsia in high-risk pregnancies across diverse populations.
Does low-dose aspirin reduce the incidence of preeclampsia in high-risk pregnancies?
Systematic Review
Does low-dose aspirin reduce the incidence of preeclampsia in high-risk pregnancies?
While low-dose aspirin can reduce the risk of preeclampsia in certain high-risk pregnancies, its efficacy is highly variable and influenced by factors like ethnicity and aspirin resistance, suggesting a need for personalized prophylaxis strategies.
Variable LDA efficacy warrants individualized use in high-risk pregnancies; challenges uniform prophylaxis and extends evidence toward ethnicity- and resistance-guided strategies.
This systematic review evaluates the efficacy of low-dose aspirin (LDA) in preventing preeclampsia in high-risk pregnancies. A comprehensive search of recent randomized controlled trials was conducted, focusing on studies published within the last five years. The review included five studies that investigated LDA at doses ranging from 60 mg to 150 mg, with outcomes measured in diverse populations. Findings indicate that LDA can reduce preeclampsia risk, particularly in specific subgroups such as non-Hispanic white women, but its efficacy is influenced by factors such as aspirin resistance, ethnicity, and biomarker levels. The review also highlights the importance of anti-inflammatory biomarkers like 15-epi-lipoxin A4 and IL-2 in understanding aspirin's mechanism of action. However, significant variability was observed across studies, suggesting that a personalized approach to aspirin prophylaxis may be necessary. This review underscores the need for future research to address gaps in aspirin efficacy across different populations and to explore biomarker-driven strategies for preeclampsia prevention.
No takes yet. Share an insight, caveat, or question.
George et al. (2025) conducted a systematic review in Preeclampsia. Low-dose aspirin vs. Placebo was evaluated on Incidence of preeclampsia. Low-dose aspirin demonstrated mixed efficacy in preventing preeclampsia across diverse high-risk populations, with significant reductions in specific subgroups like non-Hispanic white women (P = 0.007) but no universal benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: